Is microRNA 19b-1-5p related to aspirin insensitivity in platelet rich plasma?

Is microRNA 19b-1-5p related to aspirin insensitivity in platelet rich plasma? - microRNA 19b-1-5p and aspirin insensitivity in platelet rich plasma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45558

Enrollment

200

Registered

2017-06-26

Start date

2017-06-23

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aspirin insensitivity cardiovascular disease

Interventions

aspirin

cardiovascular disease

microRNA

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - age 18 years or more - use of aspirin or carbaslate calcium therapy for at least 3 months - undergoing a blood test for patient care

Exclusion criteria

Exclusion criteria: - use of other platelet aggregation inhibitors

Design outcomes

Primary

Measure	Time frame
Aspirin insensitivity measured by platelet aggregation tests	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)